GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
Thursday, August 25, 2022
GNS, a leading company in the field of biopharmaceutical drug discovery and development using "Digital Twins" and Causal AI & biosimulation technology, has announced a collaboration with Servier, a global pharmaceutical group, to advance efforts in Multiple Myeloma (MM) research, translational studies, and clinical development.
Claude Bertrand, EVP of Research and Development at Servier, stated, "This collaboration aligns with Servier's objective of accelerating drug discovery and clinical development through AI, biosimulation, and other digital initiatives. We believe that GNS' Digital Twin and unique causal AI models will enhance our understanding of MM disease biology and ultimately revolutionize our drug discovery and clinical development processes."
Joe Donahue, Chief Business Officer at GNS, expressed his excitement about the collaboration, saying, "We are thrilled to work with Servier to advance MM research and utilize our Gemini Digital Twin models to uncover novel insights and reveal the hidden biological circuitry of this disease. By collaborating with the exceptional Servier team, we aim to make a meaningful impact on the lives of patients with MM."
The collaboration will address crucial questions regarding the progression of MM in different patient subpopulations. This includes identifying the most synergistic pathways for new combination therapies and providing Servier with insights to advance their translational and clinical development efforts. Initially, the collaboration will leverage GNS' Gemini Digital Twin for MM, which has been developed using comprehensive clinico-genomic data from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study.
GNS' MM Digital Twin utilizes the abundant patient multi-modal data generated by MMRF to create a transparent, accurate, and quantified representation of complex biological mechanisms, shedding light on new disease circuitry. Through biosimulations, which are essentially computational experiments, GNS can discover new drug targets and disease mechanisms. Additionally, they can determine the efficacy of different drug candidates and understand why certain molecular profiles in patients lead to better and more durable responses. Ultimately, the MM Digital Twins have the potential to revolutionize pharmaceutical R&D by accelerating the identification of new targets and target combinations, discovering new biomarkers, and facilitating the in silico design of improved clinical trials.
